



Monday, 21 March 2022

Scheme Approved by Court

Australian Pharmaceutical Industries (ASX:API) ("API") announces that the Federal Court of Australia ("Court") has today made orders approving the scheme of arrangement between API and its shareholders (which is described in the Scheme Booklet dated 14 February 2022), under which WFM Investments Pty Ltd, a wholly owned subsidiary of Wesfarmers Limited, will acquire 100% of the shares in API that it does not already own ("Scheme").

A copy of the Court's orders will be lodged with the Australian Securities and Investments Commission on Tuesday, 22 March 2022, upon which the Scheme will become legally effective. At the same time, API will also request that quotation of API shares on the ASX be suspended from close of trading on Tuesday, 22 March 2022.

If API shareholders have any questions about the Scheme, please contact the API Shareholder Information Line on 1300 103 401 (within Australia) or +61 2 9066 4063 (outside Australia) between 8.30 am and 5.00 pm (Melbourne time) Monday to Saturday, excluding public holidays.

This announcement is authorised for release by the Board of Directors of API.

For further information:

Investors

Carolyn Ireland
API
T: +61 403 045 905

Media

Gabriel McDowell
Res Publica
T: +61 417 260 918



Australian Pharmaceutical Industries Limited
250 Camberwell Road Camberwell VIC 3124 Australia
T: +61 3 8855 3000 www.api.net.au ACN 000 004 320